Boston Children's Hospital
Boston, Massachusetts, 02115, United States
NCT Number: NCT02995759
Data strongly suggests that aggressive and early treatment of status epilepticus (SE) is crucial for seizure abortion and prevention of long-term neurologic sequelae. We propose the creation of a seizure action plan, an intervention aimed to guide daily medication use, outline pre-hospital seizure first aid and rescue medication use, and direct emergency personnel in patients' individualized SE medication algorithm, with implementation through the electronic medical record. We hypothesize that the seizure action plan will promote daily medication adherence, increase use of home rescue mediation, and improve timeliness of AED (antiepileptic drug) delivery, length of hospital stay, and ICU admission rate in episodes of status epilepticus.
Looking for future studies?
Notify Me1 month–21 year
All sexes
Observational
Boston, Massachusetts, 02115, United States
The purpose of this study is the creation, implementation, and analysis of a seizure action plan, an intervention aimed to guide daily medication use, outline pre-hospital seizure first aide and rescue medication use, and direct emergency personnel in patients' individualized status epilepticus medication algorithm, with implementation through the electronic medical record. After creation of the action plan, the primary neurologist and patient/caregiver will create a patient-specific plan. The action plan will be reviewed and updated as necessary at each regularly scheduled primary neurology clinic visit. Two studies will aim at analyzing the effectiveness of this intervention. A prospective observational cohort study of patient care process and outcomes 18 months before and 18 months after initiation of seizure action plan will analyze patients with status epilepticus requiring hospital admission and/or status epilepticus that occurs during admission at BCH and measure rescue medication prescription and application patterns, timeliness of medication administration during SE, use of appropriately dosed AEDs, rate of intubation, significant hypotension, allergic reaction, and other adverse events, and hospital length of stay and rate of ICU admissions. A second prospective observational cohort study of patient outcome variables 18 months before and 18 months after initiation of a seizure action plan obtained through parent-reported ICISS (Integrated Clinical Information Sharing System)/Trivox data, a web-based platform for tracking symptoms and response to therapy, will measure rescue medication prescription and application patterns, interval seizure frequency, effect on patient and parent quality of life, parent knowledge of AED regimen, and parent self-reported medication adherence.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Exclusion criteria include infantile spasms, not requiring AED to resolve, no hospital admission, invasive EEG monitoring, unclear seizure onset or medication administration times, episode of nonconvulsive status epilepticus.
The action plan will be electronically formatted in the EMR. After electronic creation, the primary neurologist and patient/caregiver will create a patient-specific plan.
Time frame: 18 months
Time from seizure onset to administration of AED
Time frame: 18 months
Frequency of diastat use in status epilepticus
Time frame: 18 months
Frequency of AEDs dose within 25% of suggested dose by weight/age
Time frame: 18 months
Parent-reported seizure frequency
Time frame: 18 months
Admission to Hospital and ICU rates
Time frame: 18 months
Rate of intubation, allergic reaction, significant hypotension
Time frame: 18 months
PedsQL quality of life measure taken by caregiver
Time frame: 18 months
Parent-reported knowledge of AED regimen and adherence
Boston Children's Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07689084
Brain Diseases, Central Nervous System Diseases
Marburg, Hesse, Germany
View Trial DetailsNCT05259891
Altered Level of Consciousness, Brain Diseases
Cork, Munster, Ireland
View Trial DetailsNCT03350035
Brain Diseases, Central Nervous System Diseases
Wilmington, Delaware, United States
View Trial DetailsNCT01870024
Brain Diseases, Central Nervous System Diseases
Paris, France
View Trial Details